Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

Treatment with empagliflozin significantly decreased levels of circulating PRO-C3, reflecting attenuated systemic fibroblast activation, and to what extent this indicated antifibrotic effect may underpin the clinical effects of empagliflozin remains to be elucidated.

J. Jensen, C. Andersen, M. Omar et al. · 0 citations
Open access Oct 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pre-capillary pulmonary hypertension (PH), preclinical data suggest SGLT2i may improve right ventricular (RV) function through metabolic modulation, reduced perivascular inflammation, and inhibition of vascular remodelin...

M. Ersboll, J. Kjaergaard, F. Gustafsson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.